Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Apomorphine Effects on Experimental Pain

This study has been completed.
Information provided by (Responsible Party):
Rambam Health Care Campus Identifier:
First received: December 6, 2012
Last updated: September 15, 2016
Last verified: September 2016
The aims of this study were to assess the effects of the dopamine agonist apomorphine on experimental pain models in healthy subjects and to explore the possible association between these effects and a common polymorphism within the dopamine transporter gene.

Condition Intervention Phase
Drug: Apomorphine
Phase 0

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Alterations in the Ability to Tolerate Experimental Pain by Apomorphine and Its Association With a Dopamine Transporter Polymorphism

Resource links provided by NLM:

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • Cold pain tolerance [ Time Frame: 120 minutes ] [ Designated as safety issue: No ]

Enrollment: 105
Study Start Date: July 2009
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Saline
Assessment of experimental pain models before and after treatment
Drug: Apomorphine
1.5 mg Apomorphine
Other Name: Active Comparator: Apomorphine
Active Comparator: Apomorphine
Assessment of experimental pain models before and after treatment
Drug: Apomorphine
1.5 mg Apomorphine
Other Name: Active Comparator: Apomorphine

Detailed Description:
Healthy volunteers (n=105) participated in this randomized double-blind, placebo-controlled, cross-over trial. Heat pain threshold and intensity, cold pain threshold, and the response to tonic cold pain (latency, intensity, and tolerance) were evaluated before and for up to 120 min after the administration of 1.5 mg apomorphine/placebo. A polymorphism (DAT-1) within the dopamine transporter gene (SLC6A3) was investigated.

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

- healthy and free from chronic pain of any type did not use any medications other than oral contraceptives were able to understand the purpose and instructions of the study.

Exclusion Criteria:

- any type of medical or painful condition use of medications or recreational drugs pregnancy.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01744964

Rambam Health Care Campus
Haifa, Israel
Sponsors and Collaborators
Rambam Health Care Campus
Principal Investigator: Elon Eisenberg, MD Rambam Health Care Campus, Haifa, Israel
  More Information

Responsible Party: Rambam Health Care Campus Identifier: NCT01744964     History of Changes
Other Study ID Numbers: 0078-09-RBM 
Study First Received: December 6, 2012
Last Updated: September 15, 2016
Health Authority: Israel: Ethics Commission

Keywords provided by Rambam Health Care Campus:
dopamine transporter gene
cold pressor test
experimental pain
dopamine agonist

Additional relevant MeSH terms:
Dopamine Agents
Cardiotonic Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Gastrointestinal Agents
Dopamine Agonists processed this record on October 21, 2016